Drugs / RPX2003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01702649 | Aug → Nov 2012 | bacterial infectious disease | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPX2003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01702649 ↗ |
| Known as | Biapenem | “RPX2003 (Biapenem)” NCT01702649 ↗ |
| Route | Intravenous | “Intravenous RPX2003” NCT01702649 ↗ |